Merck and Ranbaxy end drug development pact
06 Jan 2011
US drug maker Merck & Co has called off its association with Ranbaxy Laboratories that it had struck to develop anti-infective medicines, which could have fetched the Indian firm $100 million over a period of five years.
The termination of the near three year old alliance was confirmed by both Ranbaxy and MSC Pharmaceuticals, the Indian affiliate of US-based Merck & Co Inc. However the companies refused to divulge details or reasons for ending the pact.
The agreement between Merck and Ranbaxy was signed in May 2008, a month ahead of the billionaire promoters Malvinder and Shivinder Singh selling their stake in Ranbaxy to Daiichi Sankyo.
A Ranbaxy spokesperson said the agreement had been called off but details could not be given.
The pact could have seen the Indian firm net $100 million over a period of five years.
Under the agreement, Ranbaxy and Merck were to jointly work on development of clinically validated anti-bacterial and anti-fungal drug candidates.
.jpg "RBI keeps repo rate unchanged as focus remains on inflation")
.jpg "Indian Oil, Panasonic team up for lithium-ion cell production in India")
